antithyroid drugs
Thionamides inhibit thyroid hormone synthesis (effective only in high-RAIU hyperthyroidism, not destructive thyroiditis). Methimazole is first-line for almost every patient because of once-daily dosing and lower severe hepatotoxicity; reserve propylthiouracil (PTU) for first-trimester pregnancy, thyroid storm, or minor methimazole intolerance. Any major reaction (agranulocytosis, severe hepatotoxicity, ANCA vasculitis) → stop permanently and do not switch.
Counsel every patient at initiation: stop the drug immediately and seek urgent bloodwork (CBC + differential, LFTs) for fever, sore throat, mouth ulcers, jaundice, dark urine, or RUQ pain. Major reactions cross-react across thionamides — never switch from methimazole to PTU (or vice versa) after a major toxicity.
mechanism
Inhibit thyroid peroxidase (TPO) → block iodide organification and iodotyrosine coupling, halting new T4/T3 synthesis (takes 4–6 weeks to deplete preformed colloid stores). PTU additionally inhibits peripheral type 1 deiodinase (T4 → T3 conversion).
comparison and dosing
Approximate dose equivalence: methimazole 1 mg ≈ PTU 20 mg (e.g. MMI 5 mg daily ≈ PTU 50 mg BID).
| agent | usual starting dose (Graves) | thyroid storm dose | key advantages | key limitations |
|---|---|---|---|---|
| methimazole (MMI) | 5–30 mg PO once daily (scaled to free T4 elevation; maintenance 5–10 mg daily) | 60–80 mg/day (if PTU unavailable) | once-daily dosing, faster euthyroidism, lower fulminant liver failure risk, preferred in T2–T3 pregnancy & lactation | teratogenic in T1 (aplasia cutis, choanal/oesophageal atresia, omphalocele); cholestatic hepatitis; dose-dependent agranulocytosis |
| propylthiouracil (PTU) | 50–150 mg PO TID (100–300 mg/day maintenance) | 500–1,000 mg load → 250 mg q4h | blocks T4 → T3; preferred in T1 pregnancy (up to 16 weeks) and thyroid storm | severe hepatocellular necrosis / fulminant liver failure (boxed warning); TID dosing; higher ANCA vasculitis risk; intermittent Canadian supply shortages |
key points
- Baseline labs before starting: CBC with differential and liver panel (thyrotoxicosis itself causes mild transaminitis and mild neutropaenia — knowing baseline prevents false alarms; do not start if ANC <1.0 × 10⁹/L or transaminases >5× ULN).
- Routine serial CBC/LFT monitoring in asymptomatic patients is not recommended (ATA 2016) — agranulocytosis develops abruptly; symptom-driven urgent testing is what saves lives.
- Titration: recheck free T4 (± free T3) every 4–6 weeks initially (TSH stays suppressed for months), tapering to the lowest maintenance dose for 12–18 months in Graves (→ hyperthyroidism).
- Before radioactive iodine: hold methimazole 2–3 days prior to ¹³¹I ablation (ATA 2016).
- Pregnancy: PTU in T1 → methimazole from T2 at lowest dose keeping free T4 at/above upper third of normal (→ thyroid disease in pregnancy).
adverse effects and management
| reaction | MMI vs PTU | action | management |
|---|---|---|---|
| agranulocytosis (ANC <0.5 × 10⁹/L; ~0.2–0.7%, usually first 90 days) | MMI (dose-related) & PTU (idiosyncratic) | stop permanently — never switch | urgent CBC, empiric IV antibiotics if febrile, G-CSF; definitive RAI or surgery |
| hepatotoxicity (transaminases >3× ULN or rising bilirubin) | MMI (cholestatic) · PTU (hepatocellular necrosis / liver failure) | stop permanently — never switch | supportive care, hepatology consult if coagulopathy/jaundice; definitive RAI or surgery |
| ANCA-associated vasculitis (MPO-ANCA; arthralgias, purpura, GN, pulmonary haemorrhage) | PTU >> MMI | stop permanently — never switch | glucocorticoids ± immunosuppression; definitive RAI or surgery |
| minor cutaneous rash / pruritus / mild arthralgia (exclude vasculitis first) | both (~5%) | continue with antihistamine, OR trial switch to other ATD | if persistent or worsening, move to definitive therapy |
Prepared 2026-11-19. Not yet verified — check every number against the sources.